48.78
+2.4(+5.17%)
Currency In USD
| Previous Close | 46.38 |
| Open | 46.85 |
| Day High | 49.12 |
| Day Low | 46.01 |
| 52-Week High | 91.83 |
| 52-Week Low | 26.7 |
| Volume | 317,145 |
| Average Volume | 414,993 |
| Market Cap | 1.03B |
| PE | -3.93 |
| EPS | -12.4 |
| Moving Average 50 Days | 48.8 |
| Moving Average 200 Days | 55.09 |
| Change | 2.4 |
If you invested $1000 in Praxis Precision Medicines, Inc. (PRAX) since IPO date, it would be worth $116.98 as of August 23, 2025 at a share price of $48.78. Whereas If you bought $1000 worth of Praxis Precision Medicines, Inc. (PRAX) shares 3 years ago, it would be worth $808.96 as of August 23, 2025 at a share price of $48.78.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
GlobeNewswire Inc.
Aug 05, 2025 12:24 AM GMT
BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characte
Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine
GlobeNewswire Inc.
Aug 04, 2025 12:00 PM GMT
Dosing with vormatrigine over 8 weeks led to 56.3% median reduction in seizure frequency Approximately 22% of patients reached 100% reduction in seizure frequency in the last 28 days on treatment Rapid and sustained response, with over 54% of patient
Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results
GlobeNewswire Inc.
Jul 29, 2025 12:00 PM GMT
BOSTON, July 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characte